[
    [
        {
            "time": "",
            "original_text": "华熙生物首席科学家郭学平，玻尿酸两次产业革命在他手中实现",
            "features": {
                "keywords": [
                    "华熙生物",
                    "首席科学家",
                    "郭学平",
                    "玻尿酸",
                    "产业革命"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华熙生物首席科学家郭学平，玻尿酸两次产业革命在他手中实现",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "“科创板医美第一股”华熙生物：收入数据自相矛盾 应收高企研发偏低埋隐患",
            "features": {
                "keywords": [
                    "科创板",
                    "医美",
                    "华熙生物",
                    "收入数据",
                    "自相矛盾",
                    "应收高企",
                    "研发偏低",
                    "隐患"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "“科创板医美第一股”华熙生物：收入数据自相矛盾 应收高企研发偏低埋隐患",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]